MKI-3
MKI-3 is a selective microtubule-associated serine/threonine kinase-like (MASTL) inhibitor with an IC50 of 5.72 nM and a Kd of 1.89 nM. MKI-3 disrupts the MASTL-ENSA-Aurora A signaling axis. MKI-3 induces chromosomal instability, mitotic catastrophe and apoptosis (apoptosis) in cancer cells. MKI-3 is applicable to research related to triple-negative breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3084702-28-0
- Formule: C21H19N7O
- Masse moléculaire:385.42
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Aurora Kinase
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
MKI-3 inhibits cellular MASTL activity with an IC50 of 114.9 nM[1].
MKI-3 (72 h) inhibits proliferation of breast cancer cell lines 4T1, MCF7, MDA-MB-231, and BT549 with IC50 values of 42.01 nM, 93.61 nM, 91.44 nM, and 160.9 nM, respectively[1].
MKI-3 (250 nM; 12 h) suppresses the MASTL-ENSA-Aurora A signaling axis, inducing apoptotic markers, in BT549 and 4T1 breast cancer cells[1].
MKI-3 (250 nM; 24 h) activates PP2A in BT549 breast cancer cells[1].
MKI-3 (250 nM; 24 h) induces mitotic defects including aberrant nuclear morphology, multipolar spindles, and centrosome abnormalities in BT549 breast cancer cells[1].
MKI-3 (250 nM; 48 h) antiproliferative activity in BT549 breast cancer cells is mediated in part by PP2A activation, as co-treatment with 20 nM okadaic acid rescues cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BT549 and 4T1 breast cancer cells
-
Concentration:250 nM
-
Incubation Time:12 h
-
Result:Reduced levels of phosphorylated ENSA (pENSA) and phosphorylated Aurora A (p-Aurora A), and increased levels of cleaved poly(ADP-ribose) polymerase (PARP) and gamma H2A histone family member X (γ-H2AX), markers of mitotic apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4T1 syngeneic mouse model[1]
-
Dosage:8 mg/kg
-
Administration:i.p.; daily; 2 weeks
-
Result:Reduced mean nuclear size diameter.
Increased cells staining positive for phospho-histone H3 and cleaved caspase-3.
Significantly reduced phosphorylation of ENSA and Aurora A in tumor tissues, with near-complete suppression relative to controls.
Chemical Information
-
CAS No. 3084702-28-0
-
Masse moléculaire 385.42
-
Formule C21H19N7O
-
SMILES
O=C(C1=CC=C(NC2=NC3=CC=CC=C3C(NC4=NNC(C5CC5)=C4)=N2)C=C1)N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MKI-3 Related Classifications
HY-182391 Related Classifications
Powered by Bioz